Enterprise Value
2.045B
Cash
330.3M
Avg Qtr Burn
-48.55M
Short % of Float
13.64%
Insider Ownership
3.44%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KRESLADI (Marnetegragene autotemcel) /RP-L201 Details Immunodeficiency, Leukocyte Adhesion Deficiency | BLA Resubmission | |
RP-L102 Details Blood disorder, Rare diseases, Fanconi Anemia | BLA Submission | |
RP-A501 Details Immunodeficiency, Danon Disease | Phase 2 Data readout | |
RP-L301 Details Pyruvate Kinase Deficiency | Phase 2 Initiation | |
RP-A601 Details Heart disease, Arrhythmogenic cardiomyopathy | Phase 1 Data readout | |
RP-L401 Details Infantile Malignant Osteopetrosis | Failed Discontinued |